Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1008 Everest IPO EMB Thu 630p PT 930p ET
BioCentury & Getty Images


Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

Mainland China biotech raises $451M for a valuation of over $2B

Led by CEO Kerry Blanchard, mainland China biotech Everest Medicines raises $451 million in a deal that gave it a valuation of more than $2 billion. 

Oct 9, 2020 | 1:31 AM GMT

Strong local demand allowed Everest to price

Read the full 774 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers